F S&P 500
5,118.75 +12.25 (+0.24%) F Dow Jones
38,746.00 +20.00 (+0.05%) F Nasdaq
17,712.25 +105.50 (+0.60%) E-mini Russell 2000 Index Futur
2,018.40 +3.50 (+0.17%) Petróleo
83.45 +0.09 (+0.11%) Oro
2,337.40 -4.70 (-0.20%)
FibroGen, Inc. (FGEN)
Fuera de horario:
FibroGen, Inc.
409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200
https://www.fibrogen.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 486
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Thane Wettig | CEO & Director | 807.35k | N/D | 1965 |
| Mr. Juan Graham | Senior VP & CFO | 991.76k | N/D | 1977 |
| Ms. Christine L. Chung | Senior Vice President of China Operations | 1.27M | N/D | 1968 |
| Dr. Barry A. Berkowitz Ph.D. | Founder | N/D | N/D | N/D |
| Dr. John J. Hunter Ph.D. | Chief Scientific Officer | N/D | N/D | 1963 |
| David DeLucia | Vice President of Corporate FP&A and Investor Relations | N/D | N/D | N/D |
| Mr. Michael D. Lowenstein J.D., Ph.D. | Chief Legal Officer | N/D | N/D | N/D |
| Ms. Tricia Stewart | Chief People Officer | N/D | N/D | N/D |
| Mr. Kirk A. Christoffersen MBA | Chief Business Officer | N/D | N/D | 1969 |
| Dr. Rahul Rajan Kaushik Ph.D. | Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing | N/D | N/D | N/D |
Descripción
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de FibroGen, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 9; Junta: 2; Derechos del accionista: 8; Compensación: 9.
